Deniz İlHan Topcu

Deniz İlHan Topcu

Auto-generated profile, based on publicly available information

Deniz İlHan Topcu

Department of Medical Biochemistry, İzmir City Hospital , İzmir

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Clinical Biochemistry
Verified
Journal Article
Open access
EAE. Anckaert
E. Anckaert
MÖM. Öktem
M. Öktem
ATA. Thies
A. Thies
MCM. Cohen-Bacrie
M. Cohen-Bacrie
NDN.M.P. Daan
N.M.P. Daan
CMC. Milczynski
C. Milczynski
Anti-Müllenria hormone (AMH) is an established biomarker for assessing ovarian reserve and predicting response to controlled ovarian stimulation. Its routine clinical use is hampered by the variability and low-throughput of available enzyme-linked immunosorbent assays (ELISA). The presented study examined if a fully automated AMH electrochemiluminescence assay (ECLIA; Elecsys® AMH assay, Roche Diagnostics) was suitable for measuring AMH levels in healthy women and in those diagnosed with polycystic ovary syndrome (PCOS). Five European laboratories evaluated the Elecsys® AMH assay independently under routine conditions over eight months. Within-run imprecision, repeatability, intermediate precision, linearity and functional sensitivity were assessed. The Elecsys® AMH assay was compared to a manual ELISA microtiter plate format test (AMH Gen II ELISA, modified version; Beckman Coulter Inc.) using 1729 routine serum samples. AMH reference intervals were determined in 887 healthy women with regular menstrual cycle aged 20–50 years, and 149 women diagnosed with PCOS. The fully automated Elecsys® AMH assay showed excellent precision, linearity, and functional sensitivity. The coefficient of variation was 1.8% for repeatability and 4.4% for intermediate precision. Values measured with the Elecsys® AMH assay were highly correlated with the manual ELISA method (modified version) but 24–28% lower. Reference intervals showed the expected AMH decline with age in healthy women and increased AMH levels in women with PCOS. The Elecsys® AMH assay demonstrated good precision under routine conditions, and is suitable for determining AMH levels in serum and lithium-heparin plasma.

24 November 2023 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
HÇHikmet Can Can Çubukçu
Hikmet Can Can Çubukçu
DTDeniz İlHan Topcu
Deniz İlHan Topcu
SYSedef Yenice
Sedef Yenice
Artificial intelligence (AI) and machine learning (ML) are becoming vital in laboratory medicine and the broader context of healthcare. In this review article, we summarized the development of ML models and how they contribute to clinical laboratory workflow and improve patient outcomes. The process of ML model development involves data collection, data cleansing, feature engineering, model development, and optimization. These models, once finalized, are subjected to thorough performance assessments and validations. Recently, due to the complexity inherent in model development, automated ML tools were also introduced to streamline the process, enabling non-experts to create models. Clinical Decision Support Systems (CDSS) use ML techniques on large datasets to aid healthcare professionals in test result interpretation. They are revolutionizing laboratory medicine, enabling labs to work more efficiently with less human supervision across pre-analytical, analytical, and post-analytical phases. Despite contributions of the ML tools at all analytical phases, their integration presents challenges like potential model uncertainties, black-box algorithms, and deskilling of professionals. Additionally, acquiring diverse datasets is hard, and models’ complexity can limit clinical use. In conclusion, ML-based CDSS in healthcare can greatly enhance clinical decision-making. However, successful adoption demands collaboration among professionals and stakeholders, utilizing hybrid intelligence, external validation, and performance assessments.

23 January 2009 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
HSHatice Selcuk
Hatice Selcuk
MSMehmet Timur Selcuk
Mehmet Timur Selcuk
ATAhmet Temizhan
Ahmet Temizhan
OMOrhan Maden
Orhan Maden
GSGul Sevim Saydam
Gul Sevim Saydam
ASAli Sasmaz
Ali Sasmaz

10 September 2021 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
TYTuğba Yanık Yalçın
Tuğba Yanık Yalçın
DTDeniz İlhan Topçu
Deniz İlhan Topçu
ODOzlem Dogan
Ozlem Dogan
SASaliha Aydın
Saliha Aydın
NSNuran Sarı
Nuran Sarı
HAHande Arslan
Hande Arslan
Vaccines have been seen as the most important solution for ending the coronavirus disease 2019 (COVID‐19) pandemic. The aim of this study is to evaluate the antibody levels after inactivated virus vaccination. We included 148 healthcare workers (74 with prior COVID‐19 infection and 74 with not). They received two doses of inactivated virus vaccine (CoronaVac). Serum samples were prospectively collected three times (Days 0, 28, 56). We measured SARS‐CoV‐2 IgGsp antibodies quantitatively and neutralizing antibodies. After the first dose, antibody responses did not develop in 64.8% of the participants without prior COVID‐19 infection. All participants had developed antibody responses after the second dose. We observed that IgGsp antibody titers elicited by a single vaccine dose in participants with prior COVID‐19 infection were higher than after two doses of vaccine in participants without prior infection (geometric mean titer: 898 and 607 AU/ml). IgGsp antibodies, participants with prior COVID‐19 infection had higher antibody levels as geometric mean titers at all time points (p < 0.001). We also found a positive correlation between IgGsp antibody titers and neutralizing capacity (rs = 0.697, p < 0.001). Although people without prior COVID‐19 infection should complete their vaccination protocol, the adequacy of a single dose of vaccine is still in question for individuals with prior COVID‐19. New methods are needed to measure the duration of protection of vaccines and their effectiveness against variants as the world is vaccinated. We believe quantitative IgGsp values may reflect the neutralization capacity of some vaccines.

17 November 2021 in American Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
HÇHikmet Can Can Çubukçu
Hikmet Can Can Çubukçu
DTDeniz İlHan Topcu
Deniz İlHan Topcu
NBNilüfer Bayraktar
Nilüfer Bayraktar
MGMurat Gülşen
Murat Gülşen
NSNuran Sarı
Nuran Sarı
AAAyşe Hande Arslan
Ayşe Hande Arslan
Objectives: The present study aimed to develop a clinical decision support tool to assist coronavirus disease 2019 (COVID-19) diagnoses with machine learning (ML) models using routine laboratory test results. Methods: We developed ML models using laboratory data (n = 1,391) composed of six clinical chemistry (CC) results, 14 CBC parameter results, and results of a severe acute respiratory syndrome coronavirus 2 real-time reverse transcription–polymerase chain reaction as a gold standard method. Four ML algorithms, including random forest (RF), gradient boosting (XGBoost), support vector machine (SVM), and logistic regression, were used to build eight ML models using CBC and a combination of CC and CBC parameters. Performance evaluation was conducted on the test data set and external validation data set from Brazil. Results: The accuracy values of all models ranged from 74% to 91%. The RF model trained from CC and CBC analytes showed the best performance on the present study’s data set (accuracy, 85.3%; sensitivity, 79.6%; specificity, 91.2%). The RF model trained from only CBC parameters detected COVID-19 cases with 82.8% accuracy. The best performance on the external validation data set belonged to the SVM model trained from CC and CBC parameters (accuracy, 91.18%; sensitivity, 100%; specificity, 84.21%). Conclusions: ML models presented in this study can be used as clinical decision support tools to contribute to physicians’ clinical judgment for COVID-19 diagnoses.

1 July 2021 in Clinical Biochemistry
Verified
Journal Article
Closed access
DTDeniz Ilhan Topcu
Deniz Ilhan Topcu
OGOzlem Gulbahar
Ozlem Gulbahar